Abstract
Introduction
Since its original description, Large Granular Lymphocyte Leukemia (LGL) has been a subject of controversy, as to whether the disorder represents a lymphoid malignancy or an exaggerated reactive T cell process.
LGL is a chronic clonal lymphoproliferative disorder that can be phenotypically subdivided into T cell LGL and natural killer LGL.
1,2 Both subtypes, seemingly derived from distinct cell lineages, are morphologically similar, causing an accumulation of large granular lymphocytes that correspond to a mature cytotoxic effector type. The current World Health
Organization (WHO) separates chronic proliferations of LGL according to their cell lineage into two entities: chronic lymphoproliferative disorders of NK cells (CLPD-NK) and T cell large granular lymphocytic leukaemia (T-LGL), though no significant differences in clinical features or therapeutic approach are observed between them. [3] [4] [5] [6] Chronic expansions of large granular lymphocytes primarily affects elderly individuals and is likely underdiagnosed. It can be associated with severe cytopenias and other comorbidities, including autoimmune conditions and malignancies, complicating the diagnosis due to the overlap between reactive processes and clear malignant lymphoproliferation. 7, 8 While in T-LGL, objective molecular characterization relies on the detection of clonal expansions through the uniquely rearranged TCR, establishing the clonal nature of CLPD-NK is difficult and often disputed. 9,10 For both types, and distinct from typical polyclonal reactions, autoimmune phenomena are mediated by clonal, seemingly malignant immune cells. Recently, the presence of somatic mutations in STAT3
has been described in T-LGL, indicating that a significant proportion of cases represent a true malignant process.
11
Because of pathogenetic and clinical similarities, we searched for mutations in STAT3 and other related members of the STAT signaling pathway in CLPD-NK, T-LGL and in closely related conditions with possibly reactive expansions.
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Methods

Patients
Blood sample collection from patients was performed after informed consent, according to the protocols approved by the Institutional Review Board of Cleveland Clinic, The Pennsylvania State University, and The Helsinki University Central Hospital and in accordance with the Declaration of Helsinki. Thirty-seven T-LGL patients included in a previous work are not incorporated in the present study, so the mutational distribution may not be coincident (for example, 7 D661V mutations were described in the previous report, vs 3 such mutations reported herein). Based on World Health Organization guidelines, the following criteria were used to diagnose T-LGL leukemia: monoclonal TCRγ-chain rearrangement, an LGL count by peripheral blood smear of > 2000 cells/μL (not a critical criteria, patients who met all other criteria but with an LGL count < 2000 cells/μL were included); flow cytometric evidence of an abnormal CTL population characterized by expression of CD2, CD3, TCRαβ (or γ δ ), CD4 (in 2 cases), CD5 dim , CD8, CD16/56 and CD57 with negativity of CD28. Each patient must have met at least 3 of these criteria to be included in the study. In addition, TCR Vβ expansions were detected and quantitated according to criteria described previously.
12,13
Diagnosis of CLPD-NK was established based on the following parameters: blood LGL count of >700/uL and abnormal immunophenotype pattern including the presence of CD56+CD16+CD2+CD3-and granzyme B expressing cells. Persistence of the condition for more than 6 months was required. Cytopenias were classified as neutropenia (absolute neutrophil count [ANC], < 1.5 × 10 3 /μL), anemia (hemoglobin, < 10 g/dL), and thrombocytopenia (platelet count, < 100 × 10 3 /μL). Clinical responses were determined following the modified International Working Group criteria for myelodysplastic syndromes, as reported previously. 14 Time to treatment failure was defined as the interval between the start of treatment and the need for initiating a second line of therapy and/or progressive disease (including relapse after remission).
Amplification refractory mutation system (ARMS)-PCR
The presence of D661Y and Y640F mutations non detectable by direct sequencing was determined by a DNA tetra-primer ARMS assay. The primer sequences for the D661Y assay were (5' -3'): forward inner primer (G allele), AAATCATCATGGGCTATAAGATCACGG; reverse inner In addition, a separate Vβ repertoire control group of 69 volunteers was analyzed that did not differ significantly from the Beckman group or previous publications. 13 A significant clonal expansion was defined as an expansion that was greater than the mean + 3 SD of healthy controls
Apoptosis assay.
To quantitate apoptosis, we performed three-color flow cytometry with propidium iodide (Sigma), annexin-V APC (Beckman Coulter), and CD3 FITC (Beckman Coulter). Forward and side scatter analyses were used to identify the lymphocyte population in peripheral blood samples from leukemic LGLs and normal PBMCs. This lymphocyte gate then the CD3+ (T-LGL) or CD3-( CLPD-NK) gate was used to examine the population that stained positive for annexin-V APC and propidium iodide in single positive and double positive quadrants, allowing for the calculation of percent early apoptotic, apoptotic, and dead cells. Mononuclear cells were separated from peripheral blood by density gradient centrifugation, then cultured in the presence or absence of 1uM or 10uM STA-21 (Enzo Life Sciences) in RPMI + 10% FCS for 48 hours.
Microarray analysis
Mononuclear cells were separated from peripheral blood by density gradient sedimentation (Mediatech, Herndon, VA, USA).
LGL cells were separated by flow cytometric sorting using anti-VB GSE39838.
Western immunoblotting.
Peripheral blood mononuclear cells from diagnosis were lysed in a buffer composed of 50 mM Tris-Cl (pH 7.6); 5 mM EDTA; 150 mM NaCl; 0.5% NP-40; 0.5% Triton-X-100 (RIPA) 
Results
Identification of STAT3 mutations.
Using stringent diagnostic criteria we have identified a large cohort of patients with CLPD-NK and T-LGL that have been subjected to a molecular search for mutations associated with STAT3 signaling. We screened 170 cases and identified 49 STAT3 mutations in 48 cases (Fig.1) . The cohort included 120 T-LGL and 50 CLPD-NK (Table 1) , but no significant differences in distribution of STAT3 mutations were found when comparing cell-lineage subsets. Of note is that no STAT3 mutation was identified in an independent cohort of 31 cases diagnosed with idiopathic neutropenia and identifiable large granular lymphocytes in the blood smear but not fulfilling all diagnostic criteria for T-LGL or CLPD-NK.
All mutations were located in the domain of STAT3 (residues 585-688) that shares homology with Src homology 2 (SH2) domains ( Figure 1A ). The STAT3 SH2 domain mediates STAT3 dimerization via binding of phosphotyrosine residue Y705. 19 No additional somatic mutations were identified in the SH2 domain of other STAT family members (STAT1, STAT2, STAT4, STAT5a, STAT5b and STAT6) and in other JAK/STAT pathway screened genes' hotspots (gp130 exon 6, JAK2 V617F, JAK3 exons 13-17, RELA exon 5) in a screening subcohort of 40 STAT3-negative cases (20 CLPD-NKs and 20 T LGLs). All mutations were heterozygous and proved to be somatic, as they were not observed in germline DNA. One patient harbored two STAT3 mutations (D661Y and Y640F). In a case with coexisting NK and CTL components, sorting revealed that the mutation originated in the NK cell subset. Moreover, mutations were not only found in T-LGL with α /β restrictions but also in γ /δ rearranged cases: one out of two γ /δ cases included in this study was mutated (Supplemental Fig.1 ). Two mutations, Y640F and D661Y, accounted for 80% of the somatic variations found, enabling the design of a more sensitive ARMS-PCR method for each of these alterations, which allowed us to find 7 new mutated cases after analyzing all Sanger negative cases. Sequencing of cloned exon 21 STAT3 DNA products from these cases showed that the mutations were carried by one of the alleles in low proportion (<10% of clones). Titration studies highlighted a higher sensitivity of ARMS-PCR assay compared with Sanger sequencing for detecting mutations, and follow-up analyses confirmed the value of this assay in detecting minimal residual disease throughout the course of the disease in an exemplary CLPD-NK patient
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Proliferation and survival signals in STAT3 mutant LGL cases.
We then investigated whether mutant and wild type cases show signs of activation along the STAT3 signaling pathway. Western blot analysis in leukemic large granular lymphocytes from mutated or wild type specimens and mononuclear cells in controls showed that phosphorylated-STAT3 (pSTAT3) protein was most abundant in mutated cases, irrespective of the cell lineage, but also expressed at higher levels in WTs when compared with the amount in normal mononuclear cells, suggested constitutive activation in leukemic cells (Figure 2A , top). Aberrant intracellular pSTAT3 signaling also was detected in STAT3 mutant cases of T and NK origin. Counterstaining with anti-cytoplasmic-CD3 identified the lymphoid derivation of this signal (Fig 2A, bottom) .
STAT3 signaling has been considered a major intrinsic pathway for cancer inflammation, capable of inducing a large number of downstream genes that are crucial for tumor promotion.
Deregulation of the STAT3 pathway has also been specifically implicated in the pathogenesis of T-
LGL. Consequently, we examined the gene expression pattern in T-LGL leukemias compared to controls, and the impact of the presence of STAT3 mutations on the transcriptional regulation of a specific set of genes previously described. Interestingly, mutated and WT disease samples shared approximately 50% of deregulated genes, implying a role in both of deregulated apoptotic pathways. There was also a striking overexpression of 31 cancer inflammation-related genes described previously to be inducible by STAT3 ; interestingly, mutated and WT disease samples shared approx. 50% of deregulated genes; showing both mutated and non-mutated patients a preference for deregulation of apoptotic pathways. Focusing on 31 cancer-inflammation related genes described previously to be inducible 1 1 by STAT3, there was a striking pattern of overexpression of these genes; interestingly, mutant and non-mutant patients showed significant concordance (Fig. 2B, top) , suggesting that, in addition to STAT3 mutations, other mechanisms or lesions can be responsible of deregulation of this pathway.
Inhibition of STAT3 results in large granular lymphocyte apoptosis.
We then examined the effects of STAT3 inhibition in CLPD-NK and T-LGL cells using STA-21, a novel synthetic inhibitor of STAT3 dimerization, DNA binding, and STAT3-dependent luciferase reporter activity. 
Clinical correlates of STAT3 mutations.
We first studied the correlation between the detection of STAT3 and clonal size as determined by morphologic enumeration of large granular lymphocytes and Vβ TCR repertoire analysis. No correlation was found between the presence of a STAT3 mutation and the absolute large granular lymphocyte count (Table 2) . While some patients with otherwise typical cells and extreme clonal expansions did not have STAT3 mutations, overall the STAT3 mutant subset of T-
LGLs had more dominant clones, with a remarkable expansion in the panel: all mutated cases the immunodominant clone size exceeded 25% of the whole CD8 compartment, while in the nonmutated cohort 23% of cases did not reach the 25% threshold (Figure 4 ). In addition, no specific restricted Vβ subset was observed to be characteristic of each group. We performed a KIR expression analysis in half of our CLPD-NK cohort. All STAT3 mutated patients (seven) were included among the 23 out of 25 cases which showed an abnormal pattern of expression (Table 3 and Supplemental Fig.4 ). Patients with a somatic mutation in STAT3 were characterized by a higher frequency of symptomatic disease at baseline (75% vs. 40%; P<.001) and the requirement of more lines of therapy through the course of their disease (2.4 vs. 1.2; P=.03; Table 2 ). Indolent cases (as determined based on "need to treat" bases) were predominantly grouped within the non mutated patients: 59 wild type vs. 6 mutant cases. No significant differences were found when analyzing overall survival between CLPD-NK and T-LGL (Fig. 5A ) or between the mutated and non-mutated subsets (Fig. 5B) . The STAT3 mutated cohort had a shorter time to treatment failure when compared to those without mutations (Fig. 5C ), though no statistical significance was reached (p=0.128). Focusing on comorbidities, both rheumatoid arthritis and autoimmune hemolytic anemia were present in significantly higher frequencies in mutated cases while, surprisingly, pure red cell aplasia cases (PRCA) were invariably related to non-STAT3 SH2 mutant cases (Table 2) .
Discussion
Leukemic large granular lymphocytes can arise from either CTLs or NK cells and represents a likely underdiagnosed, often indolent, clonal lymphoproliferation that overlaps with reactive processes via the provisional entity of monoclonal T cell clonopathy of unclear significance.
7 While prognosis is generally good, many patients suffer from chronic morbidities due to cytopenias and the disease is, essentially, not curable. Our discovery of somatic mutations in the SH2 domain of STAT3 in T-LGL, and now also in CLPD-NK, displays its main value both in the diagnostic setting:
i) STAT3 mutations may be a useful tool to discriminate malignant NK lymphoproliferations from reactive expansions, in particular to establish clonality using STAT3 mutation as a clonal marker, and ii) the shared altered pathway and clinical behavior, strongly supports the suitability of merging both entities in one disease category; and in pathogenesis: we show that enhanced, and reversible apoptosis, is a hallmark of STAT3 lymphocytes.
Despite a similar cytotoxic effector function, NK cells, unlike T cells, mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity and do not express the surface CD3/TCR complex or go through TCR gene rearrangement. 
and activation studies suggest that STAT3 can be activated independent of key oncogenic driver mutations in its SH2 domain in a subset of patients with large granular lymphocyte disorders.
Reversal of the anti-apoptotic phenotype in response to upstream STAT3 inhibitors occurs in a proportion of patients with T-LGL. 27 We hypothesized that this effect could account for those cases without a STAT3 mutation. A downstream STAT3 selective inhibitor used in our study induced apoptosis of CLPD-NK or T-LGL irrespective of mutational status, and it appears that leukemic cells are more sensitive than their normal counterparts. In this respect, the association of .
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